Misplaced Pages

Prorenone

Clinical data
Other names	SC-23133; 3-(17β-Hydroxy-6β,7β-methylene-3-oxo-4-androsten-17α-yl)propionic acid γ-lactone
ATC code	None
Identifiers
IUPAC name (1aS,5aR,5bS,7aS,8R,10aS,10bR,10cS)-5a,7a-Dimethyl-1,1a,3',4,4',5,5a,5b,6,7,7a,9,10,10a,10b,10c-hexadecahydro-3H,5'H-spirocyclopropaphenanthrene-8,2'-furan]-3,5'-dione
CAS Number	49848-04-6
PubChem CID	170819
IUPHAR/BPS	2876
ChemSpider	149344
UNII	Y7BZ8ZY6TJ
CompTox Dashboard (EPA)	DTXSID50964446
Chemical and physical data
Formula	C23H30O3
Molar mass	354.490 g·mol
3D model (JSmol)	Interactive image
SMILES O=C6O5(3((24(/C1=C/C(=O)CC1(C)2CC3)C4)CC5)C)CC6
InChI InChI=1S/C23H30O3/c1-21-7-3-13(24)11-18(21)14-12-15(14)20-16(21)4-8-22(2)17(20)5-9-23(22)10-6-19(25)26-23/h11,14-17,20H,3-10,12H2,1-2H3/t14-,15+,16-,17-,20+,21+,22-,23+/m0/s1 Key:RRHHMFQGHCFGMH-LAPLKBAYSA-N

Prorenone (developmental code name SC-23133) is a steroidal antimineralocorticoid of the spirolactone group related to spironolactone that was never marketed. It is the lactonic form of prorenoic acid (prorenoate), and prorenoate potassium (SC-23992), the potassium salt of prorenoic acid, also exists. Prorenoate potassium is about 8 times more potent than spironolactone as an antimineralocorticoid in animals, and it may act as a prodrug to prorenone. In addition to the mineralocorticoid receptor, prorenone also binds to the glucocorticoid, androgen, and progesterone receptors. The antiandrogenic potency of prorenone in vivo in animals is close to that of spironolactone. Similarly to spironolactone, prorenone is also a potent inhibitor of aldosterone biosynthesis.

Chemistry

Synthesis

Prorenone can be synthesized via a Johnson–Corey–Chaykovsky reaction by reaction of canrenone with trimethylsulfoxonium iodide and sodium hydride.

See also

• Canrenone
• Mexrenone
• Prorenoate potassium
• Prorenoic acid
• Potassium canrenoate

References

1. ^ Claire M, Rafestin-Oblin ME, Michaud A, Roth-Meyer C, Corvol P (April 1979). "Mechanism of action of a new antialdosterone compound, prorenone". Endocrinology. 104 (4): 1194–1200. doi:10.1210/endo-104-4-1194. PMID 436757.
2. Szasz G, Budvari-Barany Z (19 December 1990). Pharmaceutical Chemistry of Antihypertensive Agents. CRC Press. pp. 87–. ISBN 978-0-8493-4724-5.
3. ^ Kamata S, Matsui T, Haga N, Nakamura M, Odaguchi K, Itoh T, et al. (September 1987). "Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives". Journal of Medicinal Chemistry. 30 (9): 1647–1658. doi:10.1021/jm00392a022. PMID 3040999.
4. Netchitailo P, Delarue C, Perroteau I, Leboulenger F, Capron MH, Vaudry H (January 1985). "Relative inhibitory potency of five mineralocorticoid antagonists on aldosterone biosynthesis in vitro". Biochemical Pharmacology. 34 (2): 189–194. doi:10.1016/0006-2952(85)90123-6. PMID 2981534.
5. US 3845041, Chinn L, "7-Halomethyl-17-hydroxy-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid gamma-lactones", issued 19 October 1974, assigned to GD Searle LLC. 

This article about a steroid is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This drug article relating to the cardiovascular system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Antiandrogens
• Antimineralocorticoids
• Cyclopropanes
• Pregnanes
• Progestogens
• Spiro compounds
• Spirolactones
• Steroidal antiandrogens
• Steroid stubs
• Cardiovascular system drug stubs